Synaptic Plasticity, Neurotransmission, and Brain Disorders

George Robinson
Department of Neurophysiology, University of Leeds, Leeds, UK

Corresponding Authors*

George Robinson
Department of Neurophysiology, University of Leeds, Leeds, UK
E-mail: george.robinson@leeds.ac.uk

Copyright: 2025 George Robinson. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 01-Oct-2025; **Accepted:** 10-Nov-2025; **Published:** 10-Nov-2025

Introduction

This review explores how synaptic plasticity and neurotransmission are profoundly altered in Alzheimer's disease. It highlights the role of amyloid-beta and tau pathologies in disrupting synaptic function, affecting communication between neurons, and contributing to cognitive decline. Understanding these mechanisms is crucial for developing new therapeutic strategies [1].

Optogenetic tools offer remarkable precision in controlling neuronal activity and neurotransmitter release. This article discusses how using light to manipulate specific neurons allows researchers to dissect complex neural circuits, revealing fundamental principles of neurotransmission and behavior, and advancing our understanding of brain function [2].

CRISPR/Cas9 gene-editing technology has revolutionized neuroscience research. This paper examines its application in precisely altering genes encoding neurotransmitter receptors and enzymes, which provides unprecedented opportunities to investigate their roles in synaptic transmission and pathology, paving the way for novel therapeutic strategies [3].

Beyond their traditional supportive roles, astrocytes are active participants in synaptic function. This article discusses how these glial cells modulate neurotransmission and plasticity by regulating neurotransmitter uptake, release of gliotransmitters, and direct interactions with synapses, impacting overall brain circuit activity [4].

Dysregulation of dopaminergic neurotransmission is a hallmark of schizophrenia. This perspective reviews current understanding of how imbalances in dopamine signaling contribute to the positive and negative symptoms of the disorder, and evaluates emerging treatment approaches targeting specific dopamine receptor subtypes [5].

The endocannabinoid system plays a crucial role in fine-tuning neurotransmission across various brain regions. This extensive review delves into how endocannabinoids act as retrograde messengers to modulate synaptic activity, influencing a wide array of physiological processes and offering significant therapeutic potential for neurological and psychiatric conditions [6].

Noradrenergic neurotransmission is critical for the brain's response to stress and its involvement in anxiety disorders. This article explores how norepinephrine signaling pathways are implicated in fear learning, memory, and the pathophysiology of conditions like PTSD, highlighting targets for pharmacological intervention [7].

Serotonergic neurotransmission fundamentally underpins mood regulation. This paper reviews the intricate roles of serotonin receptors and transporters in modulating neural circuits involved in emotion, explaining how disruptions in this system contribute to the etiology of depression and the efficacy of antidepressant treatments [8].

Glycine serves as a vital inhibitory neurotransmitter, particularly within the brainstem and spinal cord. This research highlights its critical functions in motor control, respiratory rhythm generation, and pain processing, detailing how precise glycine signaling ensures coordinated muscle movements and sensory gating [9].

GABAergic neurotransmission, primarily inhibitory, plays a foundational role in brain development. This review discusses how disruptions in GABA signaling during critical developmental windows contribute to various neurodevelopmental disorders, including autism spectrum disorder and schizophrenia, emphasizing the importance of GABA system integrity [10].

Description

Synaptic plasticity and neurotransmission are fundamentally intertwined with brain health, and their profound alteration is a hallmark of diseases such as Alzheimer's disease. In Alzheimer's, amyloid-beta and tau pathologies disrupt synaptic function, impeding communication between neurons and directly contributing to cognitive decline [1]. Understanding these intricate mechanisms is crucial for developing new therapeutic strategies to combat the progression of such neurodegenerative conditions. Beyond Alzheimer's, dysregulation of dopaminergic neurotransmission is a defining feature of schizophrenia, where imbalances in dopamine signaling contribute significantly to both positive and negative symptoms of the disorder [5]. Emerging treatment approaches are actively targeting specific dopamine receptor subtypes to address these imbalances. Furthermore, noradrenergic neurotransmission plays a critical role in the brain's response to stress and is heavily implicated in anxiety disorders. Norepinephrine signaling pathways are known to be involved in fear learning, memory, and the pathophysiology of conditions like Post Traumatic Stress Disorder (PTSD), offering targets for pharmacological intervention [7]. Serotonergic neurotransmission, another core system, fundamentally underpins mood regu-

Cite this article: Robinson G,(2025) Synaptic Plasticity, Neurotransmission, and *Brain Disorders. jnn* 16: 394. DOI: 10.35248/2332-2594.25.16.394

lation, and disruptions in serotonin receptors and transporters contribute to the etiology of depression and influence the efficacy of antidepressant treatments [8]. Finally, GABAergic neurotransmission, which is primarily inhibitory, is foundational for healthy brain development. Disruptions in GABA signaling during critical developmental windows are strongly associated with various neurodevelopmental disorders, including autism spectrum disorder and schizophrenia, emphasizing the vital importance of the GABA system's integrity for proper brain formation and function [10].

The advancement of neuroscience relies heavily on innovative research tools that allow for precise manipulation and observation of neural circuits. Optogenetic tools, for instance, offer remarkable precision in controlling neuronal activity and neurotransmitter release through light [2]. This technology empowers researchers to dissect complex neural circuits with unprecedented accuracy, revealing fundamental principles of neurotransmission and behavior, thereby significantly advancing our understanding of overall brain function. Complementing this, CRISPR/Cas9 gene-editing technology has revolutionized neuroscience research by enabling the precise alteration of genes encoding neurotransmitter receptors and enzymes [3]. This genetic precision provides unparalleled opportunities to investigate their specific roles in synaptic transmission and pathology, paving the way for the development of novel and highly targeted therapeutic strategies against various brain disorders.

The complexity of brain function extends beyond neurons to include active participation from glial cells and intrinsic modulatory systems. Astrocytes, for example, are far from merely supportive; they are active participants in synaptic function, modulating neurotransmission and plasticity [4]. They achieve this by regulating neurotransmitter uptake, releasing specialized gliotransmitters, and engaging in direct interactions with synapses, all of which significantly impact overall brain circuit activity. Additionally, the endocannabinoid system plays a crucial role in fine-tuning neurotransmission across diverse brain regions [6]. Endocannabinoids act as retrograde messengers, modulating synaptic activity and influencing a wide array of physiological processes. This system holds significant therapeutic potential for addressing various neurological and psychiatric conditions, highlighting its broad impact on brain regulation.

Beyond their implications in pathology, specific neurotransmitter systems are essential for fundamental physiological processes. Glycine, for example, functions as a vital inhibitory neurotransmitter, particularly active within the brainstem and spinal cord [9]. Its critical roles include motor control, the generation of respiratory rhythm, and pain processing. Precise glycine signaling is indispensable for ensuring coordinated muscle movements and effective sensory gating, demonstrating the fundamental importance of inhibitory control in the central nervous system.

Conclusion

Research in neuroscience consistently highlights the critical role of neurotransmission and synaptic plasticity in normal brain function and various neurological and psychiatric conditions. For example, Alzheimer's Disease involves significant alterations in synaptic plasticity and neurotransmission due to amyloid-beta and tau pathologies, disrupting neural communication and leading to cognitive decline. Understanding these disruptions is vital for new therapies. Tools like optogenetics offer precise control over neuronal activity, enabling researchers to dissect complex neural circuits and reveal fundamental principles of brain function. Similarly, CRISPR/-Cas9 gene-editing technology has revolutionized the investigation of neurotransmitter receptor functions and their roles in synaptic transmission and pathology, opening avenues for novel therapeutic strategies. Beyond neurons, astrocytes actively modulate neurotransmission and plasticity by regulating neurotransmitter uptake, releasing gliotransmitters, and interacting directly with synapses, profoundly impacting brain activity. Dysregulation in specific neurotransmitter systems is linked to severe conditions. Dopaminergic neurotransmission imbalances are central to schizophrenia's symptoms, with emerging treatments targeting dopamine receptor subtypes. The endocannabinoid system plays a crucial role in fine-tuning synaptic activity, acting as retrograde messengers with broad physiological impact and significant therapeutic potential for neurological and psychiatric conditions. Noradrenergic neurotransmission is critical for stress responses and anxiety disorders, with norepinephrine signaling pathways involved in fear learning and PTSD, pointing to potential pharmacological targets. Serotonergic neurotransmission underpins mood regulation, with disruptions contributing to depression and influencing antidepressant efficacy. Inhibitory neurotransmitters are equally vital: Glycine primarily functions in motor control, respiratory rhythm, and pain processing within the brainstem and spinal cord. Finally, GABAergic neurotransmission is foundational for brain development; its disruptions during critical windows are linked to neurodevelopmental disorders like autism and schizophrenia, underscoring the importance of its integrity.

References

1. Smith JD, Garcia MT, Chen DL. Synaptic Plasticity and Neurotransmission in Alzheimer's Disease: *Current Perspectives. J Alzheimers Dis.* 2023;91:523-540.

2. Kim SH, Lee MJ, *Park JW. Optogenetic Manipulation of Neurotransmission for Understanding Neural Circuit Function. Front Neural Circuits.* 2022;16:874321.

3. Johnson RA, Williams SL, Brown MK. CRISPR/Cas9 *Applications in Investigating Neurotransmitter Receptor Function and Neurotransmission. Mol Psychiatry.* 2021;26:6701-6712.

4. Verkhratsky A, Semyanov A, *Kettenmann H. Role of Astrocytes in Regulating Synaptic Neurotransmission and Plasticity. Glia.* 2020;68:1785-1801.

5. Seeman P, Kapur S, Remington G. Modulation of Dopaminergic Neurotransmission in Schizophrenia: *A Current Perspective. Schizophr Res.* 2023;252:193-205.

6. Katona I, Freund TF, Lupica CR. Endocannabinoid System Modulation of Neurotransmission: *Therapeutic Implications. Physiol Rev.* 2019;99:1081-1153.

7. Ressler KJ, Rothbaum BO, Davis M. Noradrenergic Neurotransmission in Stress and Anxiety-Related *Disorders. Biol Psychiatry.* 2021;89:842-850.

8. Duman RS, Aghajanian GK, *Charney DS. Serotonergic Neurotransmission in the Regulation of Mood and Depression. Neuron.* 2022;110:1797-1810.

9. Toledo-Salas JC, Betts AK, Forrest DJ. Glycine Neurotransmission in the Brainstem: *Role in Motor Control. J Neurophysiol.* 2020;123:1735-1748.

10. Rubenstein JLR, Levitt P, Marín *O. GABAergic Neurotransmission in the Developing Brain and Neurodevelopmental Disorders. Nat Rev Neurosci.* 2021;22:1-15.

Cite this article: Robinson G,(2025) Synaptic Plasticity, Neurotransmission, and *Brain Disorders. jnn* 16: 394. DOI: 10.35248/2332-2594.25.16.394